Clinical trial
Open-label Study With Bosentan in Interstitial Lung Disease
NCT00319033 · Actelion, Industry · Completed
Key facts
| NCT number | NCT00319033 |
|---|---|
| Title | Open-label Study With Bosentan in Interstitial Lung Disease |
| Official title | Long-term Open-label Study in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis Who Completed the Protocol AC-052-330. |
| Acronym | BUILD 2 OL |
| Lead sponsor | Actelion, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Interstitial Lung Disease, Scleroderma |
| Intervention type | Drug |
| Interventions | bosentan |
| Enrollment | 132 |
| Start date | Jul 1, 2004 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2006 |
| First posted | Apr 27, 2006 |
| Last update posted | Feb 3, 2025 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: